BEAM•benzinga•
Beam Therapeutics Receives FDA Orphan Drug Designation For BEAM-302, A Base Editing Therapy Targeting Alpha-1 Antitrypsin Deficiency
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga